Rashmi Gopinath

Rashmi Gopinath is a General Partner at B Capital Group where she leads the fund’s enterprise software practice in cloud infrastructure, cybersecurity, devops, and AI/ML sectors. She brings over two decades of experience investing and operating in cutting-edge enterprise technologies. She led B Capital’s investments in over 24 companies such as DataRobot, FalconX, Clari, Phenom People, Synack, Innovaccer, Labelbox, Fabric, 6Sense, Highspot, Pendo, Starburst, OwnBackup, Figment, Perimeter81, Zesty, among others.

Rashmi was previously a Managing Director at M12, Microsoft’s venture fund, where she led investments globally in enterprise software and sat on several boards including Synack, Innovaccer, Contrast Security, Frame, UnravelData, Incorta, among others.

Prior to M12, Rashmi was an Investment Director with Intel Capital where she was involved in the firm’s investments in startups including MongoDB (Nasdaq: MDB), ForeScout (Nasdaq: FSCT), Maginatics (acq. by EMC), BlueData (acq. by HPE), among others. Rashmi held operating roles at high-growth startups such as BlueData (acq. by HPE) and Couchbase (Nasdaq: BASE) where she led global business development, product and marketing roles. She began her career in engineering and product roles at Oracle and GE Healthcare. She earned an M.B.A. from Northwestern University, and a B.S. in Electrical Engineering from University of Mumbai in India.

Liam Madden

Liam Madden is Senior Vice President of Hardware and Systems Product Development at Xilinx. He leads a global team of about 1,000 engineers and oversees the strategy, design solutions, priorities and execution specific to the growth of all Xilinx Hardware and System solutions, including silicon, packaging, evaluation systems and embedded software. Madden led the development of the highly successful 28nm, 20nm and 16nm programmable families. He was responsible for the introduction of stacking technology at 28nm, leading the industry in integrating multiple devices on a silicon interposer for which he received the 2013 Semi Award. He is responsible for integrating Gb/s data converters into Xilinx products as part of the RFSOC product line aimed at revolutionizing 5G radio solutions and related products. 

Madden is a nine year veteran of Xilinx. In over a 35 year career he contributed to a range of industry leading products, including: high performance and low power microprocessors (Alpha and StrongArm at DEC), embedded processors and IP (MIPS) and consumer devices (Xbox 360 at Microsoft). 

Prior to joining Xilinx, he was a Senior Fellow at AMD where he drove AMD’s next generation chip integration methodology. 

Madden holds a BE degree from UCD, an M.Eng. degree from Cornell University. He is an Adjunct Professor at UCD, a Fellow of the Institute of Engineers Ireland and a Board Member of Science Foundation Ireland. 

John Buchanan

Dr. John Buchanan serves as the President and CEO for the Center for Aquaculture Technologies (CAT), a team with a corporate strategy of maintaining excellence in contract research and innovative R&D in aquaculture biotechnology. Prior to helping launch CAT, Dr. Buchanan spent 5 years as the Director of Research and Development at AquaBounty Technologies. Previously, Dr. Buchanan has held a series of research leadership positions at Louisiana State University, the University of California at San Diego School of Medicine, and Kent SeaTech Corporation. Dr. Buchanan has led research on the application of genetic engineering to aquaculture, the use of selective breeding, hatchery technologies, and genomics for improved productivity in finfish, the development of novel therapeutics for aquaculture, and the molecular and genetic basis for virulence in aquatic and human pathogens. He also has experience directing and conducting studies compliant with governmental regulatory standards (GLP/GCP).

Dr. Buchanan completed his undergraduate work at Texas A&M University with a B.S. in Zoology, and received his Ph.D. in Oceanography from Louisiana State University with a focus on marine biotechnology.

Specialties: business development, corporate strategy, genetic engineering, infectious disease, molecular microbiology, vaccine development, biotechnology, molecular biology, ploidy manipulation, cryopreservation, GLP, GCP, regulatory studies